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Background: Abnormal activation of the NF-κB pathway is closely related to tumorigenesis and chemoresistance.
Therefore, microRNAs that possess the NF-κB inhibitory activity may provide novel targets for anti-cancer therapy.
miR-26 family members have been shown to be frequently downregulated in hepatocellular carcinoma (HCC) and
correlated with the poor survival of HCC patients. To date, there is no report disclosing the regulatory role of
miR-26 on the NF-κB pathway and its biological significance.
Methods: The effects of miR-26b on the NF-κB signaling pathway and the chemosensitivity of cancer cells were
examined in two HCC cell lines, QGY-7703 and MHCC-97H, using both gain- and loss-of-function studies. The
correlation between miR-26b level and apoptosis rate was further investigated in clinical HCC specimens.
Results: Both TNFα and doxorubicin treatment activated the NF-κB signaling pathway in HCC cells. However, the
restoration of miR-26b expression significantly inhibited the phosphorylation of IκBα and p65, blocked the nuclear
translocation of NF-κB, reduced the NF-κB reporter activity, and consequently abrogated the expression of NF-κB
target genes in TNFα or doxorubicin-treated HCC cells. Furthermore, the ectopic expression of miR-26b dramatically
sensitized HCC cells to the doxorubicin-induced apoptosis, whereas the antagonism of miR-26b attenuated cell
apoptosis. Consistently, the miR-26b level was positively correlated with the apoptosis rate in HCC tissues. Subsequent
investigations revealed that miR-26b inhibited the expression of TAK1 and TAB3, two positive regulators of NF-κB
pathway, by binding to their 3’-untranslated region. Moreover, knockdown of TAK1 or TAB3 phenocopied the effects of
miR-26b overexpression.
Conclusions: These data suggest that miR-26b suppresses NF-κB signaling and thereby sensitized HCC cells to the
doxorubicin-induced apoptosis by inhibiting the expression of TAK1 and TAB3. Our findings highlight miR-26b as a
potent inhibitor of the NF-κB pathway and an attractive target for cancer treatment.
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Nuclear factor κB (NF-κB) is a family of transcription
factors that are implicated in many physiological and
pathological processes, including immunity, inflamma-
tion, carcinogenesis and chemoresistance [1,2]. In mam-
mals, the NF-κB family consists of five structurally
related proteins, RelA (p65), NF-κB-1 (p105/p50), NF-
κB-2 (p100/p52), RelB, and c-Rel, which form various
homodimers and heterodimers. The predominant form
of NF-κB consists of p50 and p65 subunits. In most cell
types, NF-κB is mainly trapped in the cytoplasm in an
inactive form bound to IκB proteins, the inhibitors of
NF-κB. In response to stimuli like tumor necrosis factor
alpha (TNFα) or interleukin-1β (IL1β), TGFβ-activated
kinase-1 (TAK1) and its adaptors TAB2/3 are recruited
to the receptor proximal signaling complex, leading to
the activation of IκB kinase (IKK). The activated IKK
phosphorylates IκB proteins and triggers the ubiquiti-
nation and degradation of IκB, which allows p50/p65
heterodimer to be released, translocate to the nucleus
and act as a sequence-specific DNA-binding transcrip-
tion factor. Meanwhile, IKK phosphorylates the Ser536
of p65 and thereby enhances the transactivation activity
of NF-κB [1,3]. In addition to extracellular ligands that sig-
nal through membrane receptors, the chemotherapy-
induced DNA damage also activates NF-κB in some cell
contexts [1,4]. Many potent anti-apoptosis genes are
transactivated by NF-κB [1,2]. Therefore, the activation of
NF-κB may desensitize cells to apoptosis and thereby pro-
mote cancer progression. Unfortunately, abnormal activa-
tion of the NF-κB pathway is a common phenomenon in
cancer cells [2].
MicroRNAs (miRNAs) are evolutionarily conserved
small non-coding RNAs that suppress protein expression
by binding to the 3’-untranslated region (3’UTR) of tar-
get mRNA. Several miRNAs have been reported to mod-
ify cell behavior by regulating the NF-κB pathway. For
example, miR-301a, miR-30e* and miR-182 promote
NF-κB activity and thereby enhance tumor growth, inva-
siveness or angiogenesis [5-7]. On the contrary, miR-15/
16/195 and miR-146a/b have been shown to impair NF-κB
activity, thus reducing the proliferation and metastasis
of tumor cells [8-10]. Very few miRNAs have been char-
acterized to affect chemosensitivity by regulating the
NF-κB pathway: miR-143 sensitizes colorectal cancer cells
to 5-fluorouracil treatment by downregulating ERK5, Bcl-2
and p65 expression [11]; miR-146a enhances the chemo-
sensitivity of NK/T cell lymphoma to etoposide by target-
ing TRAF6 [12]. Clearly, identification of miRNAs that
target NF-κB signaling may provide novel molecular tar-
gets for cancer therapy.
It is reported that NF-κB signaling is frequently acti-
vated in hepatocellular carcinoma (HCC) [2,13]. In order
to uncover the HCC-associated miRNAs which mayregulate the NF-κB pathway, we predicted the targets of
those deregulated miRNAs that we found in HCC tis-
sues [14], using target prediction algorithms (TargetS-
can). Among the miRNAs that were predicted to target
the regulators of NF-κB pathway, miR-26b stood out as
a potential candidate, with TAK1 and TAB3 as its puta-
tive targets. Studies from us and other groups show that
the miR-26 family (miR-26a/b) is frequently downregu-
lated in multiple types of cancer, including HCC, breast
cancer, nasopharyngeal carcinoma and melanoma [15-19].
To date, there is no report disclosing the regulatory role of
miR-26a/b on the NF-κB pathway and its biological sig-
nificance. Because of the share of common seed sequences
for target recognition, members of a miRNA family usu-
ally play similar, if not identical, roles. Therefore, we ex-
plored the impact of miR-26b on NF-κB signaling and its
biological significance. We found that miR-26b suppressed
the TNFα- and doxorubicin-activated NF-κB signaling in
HCC cells, and sensitized cancer cells to the doxorubicin-
induced apoptosis by targeting TAK1 and TAB3.
Results
miR-26b suppresses the TNFα-induced NF-κB signaling in
HCC cells
To explore the impact of miR-26b on NF-κB signaling,
miR-26b or its negative control (NC) duplex was co-
transfected with the luciferase reporter that contained
multiple NF-κB binding sites in its promoter. Compared
with the NC-transfectants, miR-26b-transfected QGY-
7703 and MHCC-97H cells displayed a significantly
lower NF-κB reporter activity in response to TNFα, the
classical NF-κB activator (Figure 1A).
It has been demonstrated that the activated NF-κB will
translocate into nucleus and induce the transcriptional
activation of anti-apoptosis genes, like c-IAP1 and c-IAP2
[20]. Consistently, we observed a prominent nuclear trans-
location of NF-κB in the TNFα-treated NC-transfectants.
However, transfection with miR-26b efficiently blocked
the TNFα-induced NF-κB nuclear translocation in both
QGY-7703 (Figure 1B) and MHCC-97H cells (Additional
file 1: Figure S1A). Furthermore, TNFα stimulation upreg-
ulated the mRNA levels of c-IAP1 and c-IAP2 in the NC-
transfectants, but this effect was significantly abrogated
by the transfection of miR-26b (Figure 1C and Additional
file 1: Figure S1B).
Next, the influence of miR-26b on the signaling mole-
cules of NF-κB pathway was investigated. As reported,
TNFα treatment significantly increased the phosphor-
ylation of IκBα and p65 in control cells (Figure 2A),
suggesting the activation of NF-κB signaling. Notably,
the TNFα-induced phosphorylation of IκBα and p65
was much less evident in the miR-26b-transfectants,
compared with the control cells (Figure 2A). In con-
trast, the antagonism of endogenous miR-26b by anti-
Figure 1 miR-26b suppresses the TNFα-stimulated NF-κB signaling. (A) miR-26b inhibited the TNFα-induced NF-κB reporter activity. HCC
cells were first transfected with NC or miR-26b duplexes, followed by co-transfection of pRL-TK and pNF-κB-Luc or pTAL-Luc, treatment with TNFα,
and analysis for luciferase activity. (B) miR-26b blocked the TNFα-induced nuclear translocation of NF-κB. QGY-7703 cells transfected with NC or
miR-26b were untreated (Ctrl) or treated with TNFα before immunofluorescent staining for p65 (red). The nuclei were stained blue with DAPI.
Scale bar, 10 μm. (C) miR-26b suppressed the TNFα-induced expression of NF-κB target genes. QGY-7703 cells transfected with NC or miR-26b
were treated with 20 ng/ml TNFα for 3 hours before qPCR analysis. *, P < 0.05; **, P < 0.01.
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TNFα-stimulated NF-κB signaling (Figure 2B).
Collectively, these data indicate that miR-26b may sup-
press NF-κB signaling by attenuating the phosphoryl-
ation of IκBα and p65.
TAK1 and TAB3 are direct targets of miR-26b
As mentioned above, TAK1 and TAB3 are the upstream
positive regulators of the NF-κB pathway [3] and their
3’UTRs contain putative miR-26b-binding sites (Additional
file 3: Figure S3), as predicted by TargetScan (Release 5.2,
http://www.targetscan.org/vert_50/, in which TAK1 and
TAB3 are designated as MAP3K7 and MAP3K7IP3, re-
spectively). We therefore examined whether TAK1 andTAB3 were direct targets of miR-26b which mediated the
suppressive effect of miR-26b on NF-κB signaling.
As shown, knockdown of either TAK1 or TAB3 gene
by small interfering RNA (siRNA) (Additional file 4:
Figure S4A and B) abated the TNFα-induced activity of
NF-κB reporter (Figure 3A) and phosphorylation of
IκBα and p65 (Figure 3B), which mimicked the effect
of miR-26b overexpression in the same cell models.
Furthermore, dual-luciferase reporter analysis showed
that the co-expression of miR-26b significantly in-
hibited the activity of firefly luciferase that carried the
wild-type but not mutant 3’UTR of TAK1 or TAB3
(Figure 3C), indicating that miR-26b may suppress
gene expression through its binding sequences at the
Figure 2 miR-26b inhibits the TNFα-induced phosphorylation of IκBα and p65. (A) Introduction of miR-26b attenuated the TNFα-induced
phosphorylation of IκBα and p65. HCC cells transfected with NC or miR-26b duplexes were treated with 20 ng/ml TNFα for the indicated time
before immunoblotting. (B) Antagonism of miR-26b enhanced the TNFα-induced phosphorylation of IκBα and p65. QGY-7703 cells transfected
with anti-NC or anti-miR-26b were treated with 2 ng/ml TNFα for the indicated time.
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on the endogenous cellular expression of its potential tar-
gets was examined. The results revealed that the introduc-
tion of miR-26b diminished the expression of TAK1 and
TAB3 at their protein (Figure 3D) but not mRNA levels
(Additional file 4: Figure S4C), whereas the antagonism of
endogenous miR-26b expression increased the protein
levels of TAK1 and TAB3 (Figure 3E).
All together, these data imply that miR-26b may re-
press the expression of TAK1 and TAB3 by binding to
their 3’UTR and thus blocking NF-κB signaling.
miR-26b abrogates the doxorubicin-induced NF-κB
activation and sensitizes HCC cells to the
doxorubicin-induced apoptosis
Doxorubicin, an anthracycline commonly used in anti-
cancer therapy, can trigger cell apoptosis by creating
DNA double-strand breaks [21]. Doxorubicin is reported
to promote the nuclear translocation and DNA-binding
activity of NF-κB in HCC cells [22], but its biological
consequence remains unknown. We found that doxorubi-
cin treatment significantly enhanced the NF-κB reporter
activity (Figure 4A), increased the levels of phosphorylated
IκBα and p65 (Figure 4B), and induced the expression of
c-IAP1 and c-IAP2 (Figure 4C). Importantly, compared
with the negative control RNA duplex (siNC)-transfection,
knockdown of p65 (Additional file 5: Figure S5) obviously
increased the apoptosis rates in the doxorubicin-treated
cells (Figure 4D). These data suggest that the doxorubicin-
triggered NF-κB activation is protective against apoptosis,
which may reduce the chemosensitivity of HCC cells.
We then explored the effect of miR-26b on the doxo
rubicin-triggered NF-κB activation. The introduction of
miR-26b significantly reduced the doxorubicin-induced
NF-κB reporter activity, compared with NC transfection
(Figure 5A). In addition, the doxorubicin-triggered phos-
phorylation of IκBα and p65 was profoundly attenuated
in miR-26b-transfectants (Figure 5B). Furthermore, theectopic expression of miR-26b effectively decreased the
doxorubicin-stimulated expression of c-IAP1 and c-IAP2
(Figure 5C). Similar to the effect of miR-26b overex-
pression, knockdown of either TAK1 or TAB3 led to de-
creased NF-κB reporter activity in the doxorubicin-
exposed cells (Figure 5D). These results suggest that
miR-26b may inhibit the doxorubicin-induced NF-κB
activation by targeting TAK1 and TAB3.
The above observations disclosed that the doxoru
bicin-triggered NF-κB activation protected cells from
apoptosis and miR-26b significantly inhibited NF-κB
signaling in HCC cells, we therefore further analyzed
whether miR-26b could sensitize tumor cells to the
doxorubicin-induced apoptosis. Compared with NC- or
non-transfected cells, the doxorubicin-induced apoptosis
was much more pronounced in miR-26b-transfectants, as
determined by the morphological examination with DAPI
staining (Figure 6A). Moreover, immunoblotting assays re-
vealed more active caspase-3 in the doxorubicin-exposed
miR-26b-tranfectants than the control cells (Figure 6B).
To verify the findings from gain-of-function study,
loss-of-function analysis was performed. In response
to doxorubicin treatment, anti-miR-26b-transfectants
displayed reduced apoptosis rate, compared with the
control group (Figure 6C). Similar to the phenotype
induced by miR-26b expression, the silencing of either
TAK1 or TAB3 enhanced the rates of doxorubicin-in
duced apoptosis (Figure 6D). These findings imply that
miR-26b may inhibit the doxorubicin-triggered NF-κB sig-
naling via targeting TAK1 and TAB3, which in turn sensi-
tizes HCC cells to the doxorubicin-induced apoptosis.
We and others have previously shown that miR-26b is
downregulated in HCC [15,16]. To confirm the associ-
ation of miR-26b with the anti-apoptosis activity of NF-κB
in vivo, we further evaluated the miR-26b levels and the
apoptosis rates in human HCC specimens. Linear re-
gression analysis disclosed a significant positive correl-
ation between the level of miR-26b and the percentage
Figure 3 miR-26b suppresses NF-κB signaling by targeting TAK1 and TAB3. (A) Knockdown of TAK1 or TAB3 inhibited the TNFα-induced
NF-κB reporter activity. QGY-7703 cells were treated and analyzed as in Figure 1A. (B) Knockdown of TAK1 or TAB3 attenuated the TNFα-induced
phosphorylation of IκBα and p65. QGY-7703 cells transfected with siNC (lanes 1, 2), siTAK1 (lanes 3, 4) or siTAB3 (lanes 5, 6) were untreated (−) or
treated with 20 ng/ml TNFα (+) for 3 minutes before immunoblotting. (C) miR-26b repressed the activity of the luciferase reporter containing the
wild-type 3’UTR of TAK1 or TAB3. QGY-7703 cells were co-transfected with NC or miR-26b duplexes, pRL-TK and a firefly luciferase reporter plasmid
carrying the wild-type (WT) or the mutant (MUT) 3’UTR of TAK1 or TAB3 before luciferase activity analysis. (D) Expression of miR-26b reduced
the protein levels of cellular TAK1 and TAB3. HCC cells were transfected with NC or miR-26b duplexes for 48 hours before immunoblotting.
(E) Antagonism of endogenous miR-26b enhanced the levels of TAK1 and TAB3 proteins. HCC cells were transfected with anti-NC or anti-miR-26b for
48 hours before immunoblotting. *, P < 0.05; **, P < 0.01.
Zhao et al. Molecular Cancer 2014, 13:35 Page 5 of 11
http://www.molecular-cancer.com/content/13/1/35of apoptotic cells in HCC tissues (Figure 6E and Additional
file 6: Figure S6), suggesting that miR-26b downregulation
may promote the survival of HCC cells in vivo.
Discussion
NF-κB is frequently activated in the various types of tu-
mors and promotes cancer development and chemore-
sistance. Therefore, miRNAs that possess the NF-κB
inhibitory activity may provide novel targets for anti-
cancer therapy.
The aberrant activation of NF-κB pathway may result
from different causative mechanisms, like inactivating
mutations or deletions of IκBα in Hodgkin’s lymphoma[23], activating mutations of NF-κB2 gene in B- and T-cell
lymphomas [23], amplifications and/or translocations of
NIK in multiple myeloma [2]. In addition to the genomic
aberrations of protein-coding genes, deregulation of the
miRNAs that regulate the NF-κB pathway also results in
the abnormal activation of the NF-κB pathway. For ex-
ample, the NF-κB activators miR-301a and miR-30e* are
overexpressed in pancreatic cancer and glioma, respect-
ively [5,6]; the NF-κB inhibitor miR-195 is downregulated
in HCC [9]. The decreased expression of the miR-26 fam-
ily members has been observed in HCC tissues and the
low miR-26a/b levels were associated with the short
survival of patients [15,16]. Our data reveal a significant
Figure 4 Doxorubicin activates NF-κB signaling and knockdown of NF-κB promotes the doxorubicin-induced apoptosis. (A) Doxorubicin
enhanced NF-κB reporter activity. HCC cells transfected with pRL-TK and pNF-κB-Luc or pTAL-Luc were untreated (Ctrl) or treated (DOX) with
doxorubicin for 12 hours before luciferase activity analysis. (B) Doxorubicin treatment increased the phosphorylation of IκBα and p65. HCC cells
were untreated (−) or treated (+) with doxorubicin for 6 hours before immunoblotting. (C) Doxorubicin stimulated the expression of NF-κB target
genes. QGY-7703 cells were untreated (Ctrl) or treated (DOX) with doxorubicin for 24 hours before qPCR analysis. (D) Knockdown of p65 sensitized HCC
cells to the doxorubicin-triggered apoptosis. HCC cells transfected with siNC or sip65 duplex were treated with indicated concentrations of doxorubicin
for 48 hours before the morphological analysis for apoptosis by DAPI staining. *, P < 0.05; **, P< 0.01; ***, P< 0.001.
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miR-26b downregulation as a novel mechanism that con-
tributes to the abnormal activation of the NF-κB pathway
in HCC cells.
Doxorubicin and its analogs, like daunorubicin, have
gained broad application for the chemotherapy of various
malignant tumors. They trigger the apoptosis of cancer
cells by interfering with the actions of DNA topoisomerase
IIα and creating DNA double-strand breaks [21]. Upon
DNA damage, ataxia telangiectasia mutated (ATM) and
sumoylated NF-κB essential modulator (NEMO) are
jointly exported from the nucleus and mediates the
TAK1/TAB2/3-dependent IKK activation [4]. Activated
IKK then induces the phosphorylation and degradation
of IκBα, which further liberates NF-κB to the nucleus
and stimulates its DNA-binding activity. In lymphoma
and cervical cancer cells, treatment with doxorubicin/
daunorubicin enhances the transactivation activity of
NF-κB [24,25]. On the other hand, although doxorubicin/
daunorubicin also induces the phosphorylation and deg-
radation of IκBα and increases the DNA-binding activity
of NF-κB in osteosarcoma and breast cancer cells [26,27],
yet they repress the NF-κB reporter activity and the
expression of the NF-κB-regulated anti-apoptosis genes.
Histone deacetylase has been shown to be recruited top65 in the daunorubicin-treated osteosarcoma cells,
which converts p65 into an active transcription repres-
sor of anti-apoptosis genes [26]. In breast cancer cells,
NF-κB induced by doxorubicin is deficient in phosphoryl-
ation and acetylation and represses the NF-κB-dependent
transcription in a histone deacetylases-independent
manner. The cellular context-dependent response calls for
a cell-type-specific analysis in determining the outcome
of doxorubicin-stimulated NF-κB signaling. Herein, we
disclosed that doxorubicin markedly increased the level of
phosphorylated p65 at the serine-536 residue and obvi-
ously activated the anti-apoptosis genes in HCC cells. Fur-
thermore, the depletion of p65 dramatically increased the
apoptosis rates of doxorubicin-exposed HCC cells, sug-
gesting that NF-κB activation impairs the chemosensitivity
of tumor cells and the inhibition of NF-κB signaling repre-
sents an effective strategy to overcome the chemoresis-
tance of HCC to doxorubicin. Consistently, it has been
shown that doxorubicin treatment activates NF-κB in
other types of cancer cell lines, and blocking NF-κB ac-
tivation sensitizes these cells to doxorubicin-triggered
apoptosis [28]. Importantly, we found that the restor-
ation of miR-26b expression significantly inhibited the
phosphorylation of IκBα and p65, reduced the NF-κB
reporter activity, blocked the nuclear translocation of
Figure 5 miR-26b abrogates the doxorubicin-activated NF-κB signaling. (A) Expression of miR-26b reduced the doxorubicin-induced NF-κB
reporter activity. HCC cells were first transfected with NC or miR-26b duplexes, followed by co-transfection of pRL-TK and pNF-κB-Luc or pTAL-Luc,
then remained untreated (Ctrl) or treated (DOX) with doxorubicin before luciferase activity analysis. (B) Introduction of miR-26b attenuated the
doxorubicin-triggered phosphorylation of IκBα and p65. HCC cells transfected with NC or miR-26b were untreated (−) or treated (+) with doxorubicin
for 6 hours before immunoblotting. (C) miR-26b suppressed the doxorubicin-induced expression of NF-κB target genes. QGY-7703 cells transfected
with NC or miR-26b duplexes were untreated (Ctrl) or treated (DOX) with doxorubicin for 24 hours before qPCR analysis. (D) Knockdown of TAK1 or
TAB3 suppressed the doxorubicin-stimulated NF-κB reporter activity. QGY-7703 cells were first transfected with the indicated siRNA duplexes, followed
by treatment and analysis as in Figure 5A. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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apoptosis genes and sensitized HCC cells to the doxoru
bicin-induced apoptosis in HCC cells. These observations
indicate miR-26b as a potent NF-κB inhibitor that may
increase the chemosensitivity of HCC cells.
TAK1 is a member of the mitogen-activated protein
kinase kinase kinase (MAP3K) family. It mediates the ac-
tivation of IKK in various cell systems [3]. Upregulation
of TAK1 is found in clear cell renal cell carcinomas and
aggressive esophageal squamous cell carcinomas [29,30].
TAB3 is markedly overexpressed in skin, testis and small
intestinal cancers [31]. Our results showed that miR-26b
could decrease the protein level of TAK1 and TAB3 by
directly binding to their 3’UTR. Considering that the
expression of miR-26 family is frequently reduced in mul-
tiple types of cancer [15-19], we suggest that miR-26b
downregulation may represent one of the mechanisms
responsible for the overexpression of TAK1 and TAB3 in
cancers.
In previous studies, miR-26a/b have been shown to
block the G1/S transition of the cell cycle by targeting
CCND2, CCNE1/2, CDK6, and EZH2 in HCC and
nasopharyngeal carcinoma [15,18,32], and to restrainmetastasis by suppressing the expression of IL6 in
HCC [33]. miR-26a/b have also been reported to induce
cell apoptosis by targeting MTDH, EZH2 and SLC7A11
in breast cancer cells and by targeting SODD in melan-
oma cells [17,19,34]. Our findings suggest that miR-
26b may also suppress NF-κB signaling and enhance
the chemosensitivity of hepatocellular carcinoma cells
by targeting TAK1 and TAB3. It is exciting to find that
a single miRNA may suppress tumor growth via multiple
mechanisms, which makes miR-26b a promising anti-
cancer target.
Conclusions
In conclusion, this study demonstrated that miR-26b
suppressed the TNFα- and doxorubicin-activated NF-κB
signaling in HCC cells, and dramatically sensitized can-
cer cells to the doxorubicin-induced apoptosis. miR-26b
exerted its inhibitory effect on the NF-κB pathway by
repressing the expression of TAK1 and TAB3. Further-
more, the downregulation of miR-26b was correlated with
the reduced apoptosis rate in HCC tissues. These findings
highlight miR-26b as a potent inhibitor of the NF-κB path-
way and an attractive target for cancer treatment.
Figure 6 miR-26b sensitizes tumor cells to the doxorubicin-induced apoptosis. (A) Introduction of miR-26b sensitized HCC cells to the
doxorubicin-induced apoptosis. Nontransfected (cell) or NC- or miR-26b-transfected HCC cells were treated with the indicated concentrations
of doxorubicin (DOX) for 48 hours before apoptosis analysis by DAPI staining. (B) miR-26b expression increased the cleavage of pro-caspase-3.
Nontransfected (cell) or NC- or miR-26b-transfected HCC cells were treated with doxorubicin for 48 hours before immunoblotting. (C) Antagonism of
miR-26b desensitized tumor cells to the doxorubicin-induced apoptosis. QGY-7703 cells transfected with anti-NC or anti-miR-26b were treated with
doxorubicin for 48 hours before apoptosis analysis by DAPI staining. (D) Knockdown of TAK1 or TAB3 sensitized HCC cells to the doxorubicin-induced
apoptosis. QGY-7703 cells transfected with the indicated siRNA duplexes were treated with doxorubicin for 48 hours before apoptosis analysis by DAPI
staining. (E) miR-26b expression is positively correlated with the rate of apoptosis in HCC tissues. The level of miR-26b was examined by real-time qPCR
and normalized to RNU6B expression. Apoptosis was analyzed using TUNEL staining. The correlation between miR-26b levels and apoptosis rates in 20
HCC tissues was determined using Spearman’s correlation coefficient. **, P < 0.01; ***, P < 0.001.
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Human tissue specimens
Histologically confirmed HCC tissues were collected from
20 patients who underwent HCC surgical resection at the
Cancer Center of Sun Yat-sen University in Guangzhou,
P.R. China. None of the patients had received any local or
systemic anticancer treatment prior to the surgery. This
study was approved by the Institute Research Ethics Com-
mittee at the Cancer Center and informed consent was
obtained from each patient.Cell lines and transient transfection
Human hepatocellular carcinoma cell lines QGY-7703 and
MHCC-97H were maintained in Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen Corp., Buffalo, NY,
USA) supplemented with 10% fetal bovine serum (FBS,
Hyclone, Thermo Fisher Scientific, Victoria, Australia).
RNA oligos were reversely transfected using Lipofecta-
mine RNAiMAX (Invitrogen, Carlsbad, CA, USA). A final
concentration of 50 nM RNA duplex or 200 nM miRNA
inhibitor was used. Transfection of plasmid DNA alone or
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mine 2000 (Invitrogen).
RNA oligoribonucleotides
hsa-miR-26b (Pre-miR miRNA Precursor Product, cat.
AM17100) and its negative control (Pre-miR Negative
Control #2, cat. AM17111) were purchased from Applied
Biosystems (Foster City, CA, USA). The sequence-specific
miR-26b inhibitor (anti-miR-26b, cat. miR20000083) and
its control (anti-NC, cat. miR02201) were obtained from
Ribobio (Guangzhou, P.R. China). All siRNA duplexes were
purchased from GenePharma (Shanghai, P.R. China).
siTAK1, siTAB3 and sip65 targeted the mRNAs of human
TAK1 [GenBank: NM_145333], TAB3 [GenBank: NM_15
2787] and p65 [GenBank: NM_001145138] genes, re-
spectively. The negative control RNA duplex (siNC) for
siRNA was non-homologous to any human genome se-
quences. The sequences of all siRNA duplexes are listed
in Additional file 7: Table S1.
Vectors and luciferase reporter assay
To quantitatively examine NF-κB activity, luciferase re-
porter plasmid containing the minimal promoter with mul-
tiple tandem NF-κB binding sites (pNF-κB-Luc, Clontech,
Palo Alto, CA, USA) and its control vector (pTAL-Luc,
Clontech) were employed. Cells were first reversely trans-
fected with 50 nM RNA duplex in a 48-well plate for
24 hours, followed by co-transfection with 10 ng pRL-TK
(Promega, Madison, WI, USA) and 50 ng pNF-κB-Luc or
pTAL-Luc for 32 hours, then remained untreated or
treated with 20 ng/ml TNFα (cat. 210-TA-010, R&D Sys-
tems, Oxon, UK) for 4 hours or doxorubicin hydrochloride
(cat. D1515, Sigma-Aldrich, St. Louis, MO, USA) for
12 hours before luciferase activity analysis.
To verify the miR-26b-targeted 3’UTR, firefly luciferase
reporter plasmids pGL3cm-TAK1-3’UTR-WT, pGL3cm-
TAK1-3’UTR-MUT, pGL3cm-TAB3-3’UTR-WTand pGL3
cm-TAB3-3’UTR-MUT were constructed. The 3’UTR seg-
ment of human TAK1 (529 bp) or TAB3 (540 bp) mRNA
that contained the putative wild-type (WT) or mutant
(MUT) miR-26b binding site (Additional file 3: Figure S3)
was PCR-amplified and inserted into the EcoRI and XbaI
sites downstream of the stop codon of firefly luciferase
in pGL3cm vector, which was created based upon the
pGL3-control vector (Promega), as previously described
[14]. The sequences of all primers are listed in Additional
file 7: Table S1. Cells cultured in a 48-well plate were co-
transfected with 20 nM RNA duplex, 10 ng pRL-TK and
20 ng firefly luciferase reporter containing the wild-type
or mutant 3’UTR of target genes for 48 hours before lucif-
erase activity analysis.
Luciferase activity was measured using the dual-luciferase
reporter assay system (Promega). pRL-TK, which expresses
Renilla luciferase, was used as an internal control to adjustfor discrepancies in both transfection and harvest effi-
ciencies. The luciferase activity of miR-26b-transfec
tants was normalized to the mean luciferase activity of
NC-transfectants.
Immunofluorescent staining for p65
Cells cultured on coverslips in a 48-well plate, were
reversely transfected with 50 nM RNA duplexes for
48 hours and remained untreated or treated with 20 ng/
mL TNFα for 10 minutes. Then the cells were fixed with
4% paraformaldehyde (PFA, cat. 16005, Sigma-Aldrich)
and stained with rabbit monoclonal antibody (mAb)
against p65 (cat. #4764, Cell Signaling Technology, CST,
Beverly, MA, USA), followed by incubation with HiLyte
Fluor 555-conjugated goat anti-rabbit IgG (cat. 28176-
05-H555, AnaSpec, Fremont, CA, USA) and nuclear
counterstaining with DAPI (cat. D9542, Sigma-Aldrich).
Fluorescent pictures were photographed with Zeiss Axio
Imager Z1 (Zeiss, Jena, Germany).
RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted from cultured cells using
TriPure Isolation Reagent (cat. 11667165001, Roche Ap-
plied Science, Germany) according to the manufacturer’s
instructions.
For real-time quantitative RT-PCR (qPCR) analysis of
mRNA, 2 μg of total RNA was subjected to DNaseI diges-
tion (Fermentas, Hanover, MD, USA) at 37°C for 30 mi-
nutes and then to heat inactivation of DNaseI at 65°C
for 10 minutes, followed by reverse-transcription using
Moloney murine leukemia virus reverse transcriptase
(Promega). mRNA level was detected using Power SYBR®
Green PCR Master Mix (Applied Biosystems) and β-actin
was used as an internal control. The primers used for
qPCR are listed in Additional file 7: Table S1. For qPCR
analysis of miRNA, cDNA was synthesized using the Taq-
man miRNA reverse transcription kit (Applied Biosys-
tems). The expression levels of miR-26b and the reference
gene RNU6B were quantified using the TaqMan Micro-
RNA Assay Kit (Applied Biosystems).
All reactions were performed on a LightCycler® 480
(Roche Diagnostics, Germany) and were run in triplicate.
The cycle threshold (Ct) values did not differ by more
than 0.5 among the triplicates. The levels of target genes
were normalized to the levels of the internal control
genes to permit the calculation of the 2-ΔΔCt value.
Immunoblotting
Cellular proteins were separated in SDS-polyacrylamide
gels, electrophoretically transferred to polyvinylidene
difluoride membranes (cat. #162-0177, Bio-Rad, Cambridge,
MA, USA), then detected with antibodies. The sources
of antibodies were as follows: mouse mAb against
IκBα (cat. #4814, CST), phospho-Ser32/Ser36 of IκBα
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(cat. BM0627, Boster, Wuhan, China); rabbit mAb for
p65 (cat. #4764, CST), phospho-Ser536 of p65 (cat. #3033,
CST) and TAK1 (cat. #5206, CST); rabbit polyclonal
antibodies for TAB3 (cat. ab85655, Abcam, Cambridge,
MA, USA) and caspase-3 (cat. #9662, CST). β-actin was
used as an internal control. All results were reproduced in
three independent experiments, and the representative
immunoblots are shown.
Apoptosis analysis
For cultured cells, 24 hours after transfection, cells were
treated with doxorubicin for 48 hours, then applied to
morphological examination and detection of caspase-3
activity. For morphological examination, the cells were
fixed with 4% PFA, stained with DAPI and those with
condensed or fragmented nuclei were considered as apop-
totic cells. At least 500 cells were counted for each sample.
The activity of caspase-3 was detected by immunoblotting.
Activated caspase-3 resulting from the cleavage of the
inactive proenzyme form was indicated as 17/19 kDa
bands below the full length caspase-3 (35 kDa) band.
For HCC tissues, TUNEL staining was performed using
the In Situ Cell Death Detection Kit (cat. 11684817910,
Roche Applied Science), according to the manufacturer’s
protocol. At least 750 cells were counted for each sample.
Statistical analysis
Data were expressed as the mean ± standard error of the
mean (SEM) from at least three independent experi-
ments. Analyses on the differences between groups were
performed using GraphPad Prism version 4.0 (Graph-
Pad Software, Inc., San Diego, CA, USA). Student’s t
test was performed to compare the differences between
two groups and one-way ANOVA was applied to com-
pare more than two groups. Correlation between the
miR-26b level and the apoptosis rate in HCC tissues
was explored using Spearman’s correlation coefficient.
All statistical tests were two-sided and P < 0.05 was con-
sidered to be statistically significant.
Additional files
Additional file 1: Figure S1. miR-26b suppresses the TNFα-stimulated
NF-κB signaling in MHCC-97H cells. (A) miR-26b inhibited the TNFα-induced
nuclear translocation of NF-κB. Cells transfected with NC or miR-26b were
untreated (Ctrl) or treated with TNFα before immunofluorescent staining
for p65 (red). The nuclei were stained blue with DAPI. Scale bar, 20 μm.
(B) miR-26b suppressed the TNFα-induced expression of NF-κB target genes.
Cells transfected with NC or miR-26b were treated with 20 ng/ml TNFα for
3 hours before qPCR analysis. *, P < 0.05; **, P < 0.01.
Additional file 2: Figure S2. Reduction of endogenous miR-26b level
by anti-miR-26b. QGY-7703 cells were transfected with anti-NC or
anti-miR-26b for 48 hours before qPCR analysis. *, P < 0.05.
Additional file 3: Figure S3. miR-26b and its putative binding
sequences in the 3’UTRs of TAK1 and TAB3. The mutant miR-26b-bindingsites (underlined) were generated in the complementary sites for the
seed region of miR-26b.
Additional file 4: Figure S4. Effects of siRNA and miR-26b on the
expression of cellular TAK1 and TAB3 in QGY-7703 cells. (A-B) siTAK1 and
siTAB3 silenced the expression of TAK1 and TAB3 proteins. Cells were
transfected with siNC or siRNA targeting TAK1 (A) or TAB3 (B) for 48 hours
before immunoblotting. (C) miR-26b had no effect on the mRNA level of
TAK1 and TAB3. Cells were transfected with NC or miR-26b duplexes for
48 hours before qPCR analysis.
Additional file 5: Figure S5. Knockdown of endogenous p65 protein
by siRNA. HCC cells were transfected with siNC or sip65 duplexes for
48 hours before immunoblotting.
Additional file 6: Figure S6. Representative images of TUNEL staining
in HCC tissues. Apoptotic cells exhibited brown staining. Scale bar, 50 μm.
Additional file 7: Table S1. Sequences of RNA and DNA Oligonucleotides.
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